CN1842335A - 用于治疗高眼压的眼用组合物 - Google Patents

用于治疗高眼压的眼用组合物 Download PDF

Info

Publication number
CN1842335A
CN1842335A CNA2004800243370A CN200480024337A CN1842335A CN 1842335 A CN1842335 A CN 1842335A CN A2004800243370 A CNA2004800243370 A CN A2004800243370A CN 200480024337 A CN200480024337 A CN 200480024337A CN 1842335 A CN1842335 A CN 1842335A
Authority
CN
China
Prior art keywords
alkyl
chemical compound
heterocyclic radical
aryl
randomly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800243370A
Other languages
English (en)
Chinese (zh)
Inventor
M·H·陈
J·B·多赫尔蒂
L·刘
S·纳塔拉彦
R·M·泰内博尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN1842335A publication Critical patent/CN1842335A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
CNA2004800243370A 2003-09-04 2004-08-31 用于治疗高眼压的眼用组合物 Pending CN1842335A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50009003P 2003-09-04 2003-09-04
US60/500,090 2003-09-04

Publications (1)

Publication Number Publication Date
CN1842335A true CN1842335A (zh) 2006-10-04

Family

ID=34312180

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800243370A Pending CN1842335A (zh) 2003-09-04 2004-08-31 用于治疗高眼压的眼用组合物

Country Status (7)

Country Link
US (1) US7494983B2 (US07494983-20090224-C00063.png)
EP (1) EP1663221A4 (US07494983-20090224-C00063.png)
JP (1) JP2007504236A (US07494983-20090224-C00063.png)
CN (1) CN1842335A (US07494983-20090224-C00063.png)
AU (1) AU2004271978B2 (US07494983-20090224-C00063.png)
CA (1) CA2537430A1 (US07494983-20090224-C00063.png)
WO (1) WO2005025568A1 (US07494983-20090224-C00063.png)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528163B2 (en) 2002-11-08 2009-05-05 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
EP1663987B1 (en) * 2003-09-04 2009-03-18 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
AU3693789A (en) 1988-05-10 1989-11-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) New ophthalmic preparation for treating glaucoma
ATE101342T1 (de) 1988-09-06 1994-02-15 Kabi Pharmacia Ab Prostaglandinderivate zur behandlung des gruenen stars oder einer okularen hypertension.
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
JPH08511024A (ja) 1993-06-08 1996-11-19 バイディ ファーマシューティカルズ 眼内圧を低下させる方法および組成物
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5925342A (en) 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
EP1114816A4 (en) 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
AU1293101A (en) 1999-12-22 2001-07-03 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
AU1918001A (en) * 2000-03-17 2001-10-03 Alcon Universal Ltd 5-hydroxy indazole derivatives for treating glaucoma
EP1268438A1 (en) 2000-03-17 2003-01-02 Alcon, Inc 6-hydroxy-indazole derivatives for treating glaucoma
EP1186287A1 (en) 2000-03-31 2002-03-13 Toray Industries, Inc. Hair growth or hair formation controlling agents
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
CA2429850C (en) 2000-11-27 2008-12-30 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
BR0210241A (pt) * 2001-06-01 2004-08-10 Alcon Inc Piranoindazóis e seu uso no tratamento de glaucoma
US7528163B2 (en) * 2002-11-08 2009-05-05 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
EP1479675A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors

Also Published As

Publication number Publication date
AU2004271978A1 (en) 2005-03-24
EP1663221A4 (en) 2009-04-22
US20070027188A1 (en) 2007-02-01
AU2004271978B2 (en) 2009-02-05
US7494983B2 (en) 2009-02-24
JP2007504236A (ja) 2007-03-01
CA2537430A1 (en) 2005-03-24
WO2005025568A1 (en) 2005-03-24
EP1663221A1 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
CN1266138C (zh) 促旋酶抑制剂和其用途
CN1025999C (zh) 咪唑并[4，5-b]喹啉氧烷酰胺的制备方法
CN1061041C (zh) 哌啶类衍生物
CN1206228C (zh) 作为nos抑制剂的n－杂环衍生物
CN1816530A (zh) 用于治疗高眼压症的眼用组合物
CN1100534C (zh) 2－(1h－4(5)－咪唑基环丙基衍生物及含该衍生物的药物组合物和其制备方法
CN1745077A (zh) 促旋酶抑制剂及其用途
CN1294577A (zh) 钾通道抑制剂
CN1329599A (zh) 作为钾通道调节剂的3－取代－4－芳基喹啉－2－酮衍生物
CN1344257A (zh) cGMP磷酸二酯酶的稠合吡啶并哒嗪抑制剂
CN1934083A (zh) 作为肾素抑制剂用于治疗高血压的5－氨基－4－羟基－7－(1h－吲哚基甲基)－8－甲基壬酰胺衍生物
CN1102648A (zh) 取代的单-和双-吡啶基甲基吡啶酮类化合物
CN1871242A (zh) 作为mch r1拮抗剂用于治疗肥胖症、糖尿病、抑郁症和焦虑的3－(4－(氨基苯基)噻吩并嘧啶－4－酮衍生物
CN1455769A (zh) 用作β－3肾上腺素能受体激动剂的环胺磺酰胺
CN1681789A (zh) 1－吡啶－4－基－脲衍生物
CN1819846A (zh) 包含毒蕈碱性受体激动剂的经皮肤吸收的眼用制剂
CN1206407A (zh) 取代的乙烯基吡啶衍生物和含有它们的药物
CN101035537A (zh) 治疗眼部疾病的组合物和方法
US7279490B2 (en) Ophthalmic compositions for treating ocular hypertension
CN1863773A (zh) 四氢吡啶衍生物
CN1329613A (zh) 新的化合物
CN1780836A (zh) 作为血管紧张肽原酶抑制剂的新型二氮杂双环壬烯和四氢吡啶衍生物
CN1845914A (zh) 用于治疗眼压过高的眼用组合物
CN1042632C (zh) 吡啶酮羧酸衍生物、制备它们的中间体及药物组合物
CN1856305A (zh) 吡啶衍生物及其作为尾加压素ⅱ拮抗剂的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20061004